These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31735949)

  • 41. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.
    Nabhan C; Peterson LA; Kent SA; Tallman MS; Dewald G; Multani P; Gordon LI
    Leuk Lymphoma; 2002 Nov; 43(11):2145-9. PubMed ID: 12539741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Liebenguth P; Vogt Temple S
    Semin Oncol Nurs; 2006 Nov; 22(4):257-66. PubMed ID: 17095402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective.
    Press OW
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):10-21. PubMed ID: 12728403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.
    Ku M; Chong G; Hawkes EA
    Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW; Fisher RI
    Oncology (Williston Park); 2007 Feb; 21(2):203-12; discussion 214, 217, 221. PubMed ID: 17396483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Future directions in radioimmunotherapy for B-cell lymphoma.
    Horning SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
    Blum KA; Bartlett NL
    Expert Opin Biol Ther; 2004 Aug; 4(8):1323-31. PubMed ID: 15268665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radioimmunoconjugates for treating cancer: recent advances and current opportunities.
    Bourgeois M; Bailly C; Frindel M; Guerard F; Chérel M; Faivre-Chauvet A; Kraeber-Bodéré F; Bodet-Milin C
    Expert Opin Biol Ther; 2017 Jul; 17(7):813-819. PubMed ID: 28438082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up.
    Martínez A; Martínez-Ramirez M; Martínez-Caballero D; Beneit P; Clavel J; Figueroa G; Verdú J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(1):13-19. PubMed ID: 27422155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Whelton S
    Nurse Pract; 2007 Dec; 32(12):35-8. PubMed ID: 18043410
    [No Abstract]   [Full Text] [Related]  

  • 52. [New trends in the diagnosis and treatment of malignant lymphoma].
    Tobinai K
    Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Feb; 63(3):81-8. PubMed ID: 12692961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Durable responses reported with radioimmunotherapy in low-grade non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2002 Mar; 16(3):304, 326. PubMed ID: 15046389
    [No Abstract]   [Full Text] [Related]  

  • 55. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
    Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: best of both worlds?
    Boerman OC; Oyen WJ; Corstens FH
    Cancer Biother Radiopharm; 2000 Feb; 15(1):1-5. PubMed ID: 10740647
    [No Abstract]   [Full Text] [Related]  

  • 57. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
    Conti PS
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):2-3. PubMed ID: 14762737
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2000 Jul; 14(7):1009, 1039. PubMed ID: 10929588
    [No Abstract]   [Full Text] [Related]  

  • 59. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
    Postema EJ
    J Nucl Med; 2004 Dec; 45(12):2126-7; author reply 2127. PubMed ID: 15585492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.